Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
MWN-AI** Summary
Shineco Inc. (NASDAQ: SISI) recently made headlines with two significant strategic advancements aimed at bolstering its growth trajectory. The company announced an $8.7 million technology services contract through its subsidiary, Xi'an Dong'ao Health Management Co., Ltd., with Xinke Future Biotechnology. This contract focuses on the research and development of innovative microalgae-derived extracellular vesicles technology, set to run from August 2025 to December 2026. A key aspect of this agreement is its phased payment structure, tied to achieving research milestones, thereby ensuring stable revenue streams.
In conjunction with this development, Shineco is also advancing its international cooperation efforts. A high-level delegation from Singapore's BICC, a leading biotechnology firm, recently visited Dong'ao Health to explore collaborative opportunities. The talks resulted in a consensus to establish a joint laboratory and a technology exchange system, facilitating the design of stem cell transfusion centers and leveraging BICC’s extensive network across Southeast Asia to enhance Shineco's market footprint.
These synchronized efforts underscore Shineco's dual growth engines—technology advancement and ecosystem synergy. The collaboration aims to not only establish cutting-edge biocellular technology but also create solid domestic and international market channels. CEO Jennifer Zhan reaffirmed the company’s strategy, highlighting the importance of utilizing technology commercialization for immediate revenue while fostering long-term profitability through market expansion.
Shineco's combined initiatives position it well for future growth, reflecting its commitment to advancing the development of high-quality health products and services. With regular updates anticipated, investors will be keenly watching the impacts of these strategic moves on Shineco's performance.
MWN-AI** Analysis
Shineco Inc. (NASDAQ: SISI) has recently made significant strides with an $8.7 million technology services contract and a strategic alliance with Singapore’s BICC, positioning itself for robust growth in the burgeoning biocellular market. Investors should consider these developments as catalysts for potential value appreciation in SISI shares.
The contract with Xinke Future Biotechnology, aimed at developing microalgae-derived extracellular vesicles, not only bolsters Shineco's revenue pipeline with phased payments but also highlights the company's commitment to advancing its research and development capabilities. The project's goal of transitioning from lab to market with at least two therapeutic products underscores a strategic shift towards monetizing innovative technologies, aiming to establish a sustainable revenue stream.
Furthermore, the alliance with BICC introduces a significant layer of value, combining Shineco's domestic strengths with BICC's extensive Southeast Asian distribution network. This partnership is poised to enhance Shineco’s market reach, leveraging BICC’s established channels to accelerate international expansion. The commitment to forming a joint laboratory and a technology exchange mechanism suggests a comprehensive approach to innovation and commercialization, critical for staying competitive in the biotech landscape.
With a dual-engine growth strategy focusing on both technology development and ecosystem synergy, Shineco is not only securing immediate financial momentum but also setting the stage for long-term profit growth. As the market increasingly values companies with solid partnership frameworks and innovative pipelines, SISI shares could become attractive for long-term investors.
In summary, the strategic advancements at Shineco—namely the substantial technology deal and the collaboration with BICC—provide clear pathways for revenue growth and international expansion. Investors should monitor this stock closely as these developments may significantly enhance its market position and financial performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
PR Newswire
BEIJING , Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's leading biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10 . The parties reached a broad consensus on key collaboration areas, including establishing a joint laboratory and a technology exchange mechanism, marking a substantive step forward in Shineco's "technology industrialization and global synergy" strategy in the biocellular field.
As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025 , to December 31, 2026 , with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale (e.g., hectoliter-scale) separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market.
This contract provides clear near-term financial momentum for Shineco. The total value of US$8.7 million will be paid in phases, with an initial payment of US$560,000 already received. Subsequent payments are tied to R&D milestones, ensuring stable revenue recognition and creating long-term profit growth drivers through the "develop once, deploy multiple times" nature of the technology.
"This contract is a powerful validation of our strategy to monetize cutting-edge research and create near-term revenue," said Jennifer Zhan , CEO of Shineco. "Coupled with our strategic alliance with BICC, it provides two clear, synergistic engines for growth that strengthen our domestic business while accelerating our international expansion."
Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10 , including Chairman Mr. Yang Shengnan, CEO Ms. Barbara Tan , CFO Mr. Jon Lim , Chief Scientist Mr. Chen Yanming, and shareholder Mr. Chen Laifu.
The delegation conducted on-site inspections of Dong'ao Health's four core segments—the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"—to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in Southeast Asia with Dong'ao Health's domestic wellness channels, and co-establish stem cell transfusion centers to promote standardized clinical services.
These dual developments exemplify Shineco's two-pronged strategy of "technology development plus ecosystem synergy." Technologically, the partnership combines complementary R&D capabilities and application scenarios. From a market perspective, the contracted revenue and BICC's international channels create a strategy of "a solid domestic base + expansion into new international markets." Financially, the deal improves short-term cash flow and enhances long-term profitability through technology leverage and market expansion.
"These advancements demonstrate the effective operation of our complete value chain from technology to industry to capital," CEO Jennifer Zhan emphasized. "Shineco remains committed to deepening our technology industrialization efforts and advancing international partnerships to deliver sustainable returns for our shareholders."
Shineco will provide regular updates on the contract's execution and the collaboration with BICC in accordance with NASDAQ disclosure rules.
About Xi'an Dong'ao Health Management Co., Ltd.
Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols.
About BICC Pte Ltd
BICC Pte Ltd is a Singapore -based innovative biotechnology holding company with an extensive commercial network of over 3,000 agents across Southeast Asia , which provides a powerful distribution channel for its portfolio of advanced therapies and wellness products. Founded in 2024, the company unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. Leveraging its strategic presence across Asia and proprietary technologies—including patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications—BICC is positioned at the cutting edge of integrated health solutions. For more information about BICC, please visit www.BICC.sg .
About Shineco, Inc.
Shineco, Inc. is dedicated to improving quality of life through the development and provision of safe, efficient, and high-quality health and medical products and services. The Company's core business focuses on induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information, please visit www.biosisi.com .
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
Email: secretary@shineco.tech
Phone: +86-10-68130220
SOURCE Shineco,Inc.
FAQ**
How does the recent $8.7 million tech deal enhance Shineco Inc. SISI's position in the induced pluripotent stem cell technology market, and what impact is it expected to have on the company's revenue and growth trajectory?
In what ways will the alliance between Shineco Inc. SISI and Singapore's BICC facilitate international market expansion and establish a joint laboratory for R&D in biocellular technologies?
What specific regulatory challenges does Shineco Inc. SISI anticipate in transitioning the microalgae-derived extracellular vesicles technology from the lab to market availability?
How does the dual strategy of "technology development plus ecosystem synergy" employed by Shineco Inc. SISI contribute to its long-term profitability and sustainable shareholder returns?
**MWN-AI FAQ is based on asking OpenAI questions about Shineco Inc. (NASDAQ: SISI).
NASDAQ: SISI
SISI Trading
-18.91% G/L:
$5.53 Last:
24,594 Volume:
$5.78 Open:
